Yes, a single medicine can sometimes use the same carton structure for both Europe and the United States. However, the printed pack, coded data, and supply chain setup often require separate versions. That is the short answer to DSCSA versus EU FMD. Both systems operate at the saleable pack level and utilize a 2D barcode, but their product codes, data syntax, verification routes, and market details differ significantly. Because of this, teams should treat physical pack design and market-specific execution as two linked, yet separate, workstreams from the start.
• One carton size may work for both markets, but the artwork and code content often need to be split.
• The same medicine may require different coded identities because NDC versus EU product code rules are not identical.
• EU packs frequently require anti-tampering features and utilize the EU medicines verification system through hub and national routes.
• US flows rely on DSCSA package-level tracing, pharmaceutical electronic transaction data, and saleable unit verification between trading partners.
• Early decisions regarding the data owner, release roles, aggregation needs for US pharma, and country variants help reduce launch risks.
DSCSA versus EU FMD: what both systems share at the pack level
The shared foundation is simple. Both systems identify a saleable medicine pack with a 2D data carrier, and both rely on key data elements such as a product code, serial number, batch or lot number, and expiration date. This similarity helps at the start of a dual-market project because the overall pack logic appears aligned. However, US and EU serialization differences emerge quickly when teams review the exact market rules, coded content, and data flow behind the packaging.
In practical terms, DSCSA versus EU FMD projects often allow for a single carton structure, but they do not always permit one printed version or a single serialization setup. The code format, human-readable text, and market-specific labels can all differ. Therefore, a shared outer shape does not guarantee shared execution. Teams should confirm the current requirements for their exact product, market route, and partner setup before packaging line decisions are finalized.
DSCSA versus EU FMD: how the EU route works in practice
What goes on the pack
For affected EU packs, the carton typically requires a unique identifier and an anti-tampering feature. The unique identifier is embedded in the 2D code and also appears in human-readable text. Meanwhile, the anti-tampering feature indicates whether the pack has been opened or altered before being supplied. Because of this, the structural and closure designs need early review, especially when the same base pack is intended for more than one market.
How the data moves
The EU route uses the EU medicines verification system. In plain language, the serialization data goes through an authorized onboarding partner, then to the European Hub, and finally to national verification systems. This route matters because while the pack may look almost identical to a US version on the production line, the data path behind it is fundamentally different. That difference directly affects planning, handovers, and error control.
When checks happen
In many EU flows, the main verification and decommissioning steps occur when the medicine is supplied to the public. Additional checks can also take place earlier in the supply chain. Since the exact process depends on the product and its supply route, project teams should define roles, timing, and reporting points in advance rather than assuming one market model will seamlessly fit another.
Country details that can change the pack
Europe adds local complexity because some countries may require a European national reimbursement number, or another local identifier, either within or alongside the unique identifier setup. Readable text can also vary by country. As a result, a single EU base pack can easily evolve into several versions. This is one reason why dual-market pharmaceutical artwork often requires tighter control than teams initially expect.
DSCSA versus EU FMD: how the US route works in practice
What DSCSA focuses on
In the United States, the DSCSA focuses on package-level tracing throughout the supply chain. In simple terms, authorized trading partners exchange electronic records as a product moves from one step to the next. This includes pharmaceutical electronic transaction data and processes that support saleable unit verification. For broader background on the US regulatory environment, teams can review FDA good manufacturing practices as a related topic, although GMP compliance does not replace the need for product traceability planning.
Product coding and event handling
The US product identifier uses its own specific market code, so the NDC versus EU product code question must be answered early. A medicine can be medically identical in both markets, but its coded identity on the pack may still need to change. Furthermore, US routes require specific actions when a product is deemed suspect or illegitimate. Because of this, carton coding, data ownership, and event handling protocols should be clearly defined before operations begin.
This is a core risk area in DSCSA versus EU FMD planning. If the right medicine is packed into a carton with the wrong code, the physical product may be correct, but its market identity is invalid. Therefore, coded fit and physical fit must always be treated as separate verification checks when packing for dual-market serialization projects.
Why aggregation matters in operations
Aggregation in US pharma is often a practical operational necessity. Because cases and pallets move through busy distribution channels, teams must keep the links between the unit pack, case, and pallet entirely clear. In this way, DSCSA package-level tracing can continue to support handling, shipping, and investigation efforts even when outer packaging levels are moved. This should not be viewed as a direct copy of an EU FMD requirement, as the legal logic and system design are different even if certain packaging tasks look similar.
Dates to verify
DSCSA timing requirements have shifted over time, meaning teams should always confirm the latest FDA position. One current planning focal point is the November 27, 2026, deadline for small dispensers, which refers to the exemption timeline for eligible entities. This can help downstream planning, but it must still be cross-checked against current updates before finalizing launch or supply decisions.
DSCSA versus EU FMD: where shared artwork stops working
Shared carton structure versus market-specific execution
A single carton shape can often remain unchanged if the product size, barrier requirements, filling logic, and handling needs align. Even so, the printed pack typically needs to be split into multiple versions. This is because dual-market pharmaceutical artwork must reflect market-specific product codes, support text, labels, and coding rules. In DSCSA versus EU FMD work, the physical structure may remain shared, while the market execution does not.
The main reasons for split versions
The primary drivers for split versions are different product codes, national data elements, human-readable information, and local market labels. While code placement might remain similar, the encoded content can change drastically. Anti-tampering expectations and supply chain data exchange requirements also demand separate reviews. Consequently, controlled variant management is crucial, especially when one base design feeds into more than one pack version. In this context, life-cycle management for multi-market packs can help teams reduce obsolete stock and maintain clear version control.
When shared pack architecture ends and execution splits, handovers become a significant risk. Different teams may own the design, components, coding, packing, and release steps. We design packs in-house, optimize designs for manufacturability, produce packaging components, and provide primary and secondary packaging, including serialization. For teams wanting fewer handovers across the packaging journey, our primary and secondary pharmaceutical packaging solutions demonstrate how a single point of contact can streamline both planning and execution.
Main project risk
A simple example illustrates this issue. Imagine a single medicine intended for both markets, featuring the same blister, the same leaflet count, and the exact same carton size. If a US batch is placed into an EU-coded carton, the medicine inside is correct, but the market code is fundamentally wrong. This highlights one of the clearest US and EU serialization differences at the pack level: the error is not about physical fit. Rather, it is about identity, traceability, and the mandatory route the pack must follow after release.
Building a dual-market pack plan
Questions to answer before line setup
Teams must answer several practical questions before line setup begins. Which markets will receive the product? Which product codes apply? Who owns the serialization data? What specific reports are required? Who releases the product at each stage? What level of aggregation is needed in the US route? What country variants are necessary in Europe? These points shape the entire project, as successful packaging execution completely depends on them.
Planning physical structure before data rules
It is helpful to establish the pack architecture early, as late changes to bundle logic, case counts, or hierarchy can force costly data and artwork rework. A stable physical format makes the serialization route much easier to define. A useful example is the 4-in-1 separable packaging case, which illustrates how a planned pack hierarchy can support handling long before final execution details are locked in.
Where one partner can reduce handovers
Dual-market projects often struggle when work is handed off from one function to another. The design team may approve one layout, procurement might source a different component version, and packaging could receive the data rules too late. We eliminate these gaps because we cover design, manufacturability, component production, and primary and secondary packaging, along with serialization. If a customer prefers to insource, we can even supply the packaging machinery, ensuring the packaging logic stays perfectly aligned throughout the project.
Dual-market matrix for project teams
| Topic | EU pack | US pack | Shared or split decision |
|---|---|---|---|
| Pack format | May match the US structure if product and handling needs are similar | May match the EU structure if line setup and logistics allow | Often shared |
| Product code | EU market code, sometimes requiring local numbers | US market code, usually NDC-based | Split |
| Serial number format or syntax | Market-specific data rules apply | Market-specific data rules apply | Usually split |
| Batch or lot data | Included on the pack | Included on the pack | Shared concept, market review needed |
| Expiry format | Included on the pack; local presentation may vary | Included on the pack; local presentation may vary | Shared concept, artwork review needed |
| Anti-tampering feature | Expected for affected packs | Reviewed separately by route and pack type | Often split in execution |
| Artwork version | May require country variants | A US-specific version is often needed | Usually split |
| Human-readable text | Can vary by market and country | US-specific text applies | Split |
| Data owner | Must be defined by the project team | Must be defined by the project team | Shared question, route-specific answer |
| Aggregation level | Reviewed by operating model | Often needed in practice | Usually split |
| Electronic reports or transaction data | Verification routes through central and national repositories | Electronic transaction data exchanged with trading partners | Split |
| Verification point | Often at the point of supply to the public, with other checks in the chain | Saleable unit verification within supply chain processes | Split |
| Release responsibility | Must be defined by the product and route | Must be defined by the product and route | Shared planning topic, split execution |
If you are scoping a dual-market launch, bring your destination markets, expected volumes, artwork status, and data responsibilities into the first discussion. This makes planning much faster because open questions become visible early on. If you want to map out your packaging route, you can discuss a dual-market packaging project with us, and we will focus on structure, components, packing, and the serialization scope.
Questions teams often ask about dual-market serialization
Can one carton design work for both markets?
Yes, the carton structure can sometimes stay the same. However, the artwork and coded data often require separate versions because the product code, human-readable text, and local market details differ. Therefore, a shared shape does not always mean a shared printed pack.
Is aggregation required in both systems?
Teams should review this carefully. In many US flows, aggregation is an operational necessity because case and pallet movements must remain linked to pack-level data. In the EU, the logic is fundamentally different, so aggregation should not be described as a direct legal match to EU FMD requirements. Ultimately, the right answer depends on the specific route, warehouse model, and partner needs.
Can the same product code be used in Europe and the US?
Usually, no. The NDC versus EU product code discrepancy is one of the primary reasons a single medicine needs different coded pack identities depending on the market. In some EU countries, local identifiers may also play a crucial role, adding another layer of complexity to artwork and code planning.
Do DSCSA dates stay fixed?
No. Dates and exemptions have changed over time. One useful current marker is the exemption for eligible small dispensers through November 27, 2026. Still, teams should always confirm the latest FDA updates before finalizing any supply or launch decisions.
Request a free sample now!
